<DOC>
	<DOC>NCT00036257</DOC>
	<brief_summary>The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.</brief_summary>
	<brief_title>Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>1. Relapsed or refractory chronic lymphocytic leukemia. 2. Patients must have either intermediate or high risk chronic lymphocytic leukemia according to the Rai Staging System. 3. Must have failed at least 1 prior chemotherapy regimen (at least 1 of which included fludarabine) for CLL. 4. No prior therapy within 4 weeks prior to entering the study. Patients must have fully recovered from the acute effects of prior therapy. 5. Platelet count = 75,000/mm3 , hemoglobin = 8 gm/dL. 6. Expected remaining life span &gt; or = three months. 7. ECOG performance status 0 2. 8. 18 years or of legal age. 9. Male patients or nonpregnant and nonlactating female patients, who are either using adequate birth control, are surgically sterile or postmenopausal. 10. Negative serum pregnancy test, if fertile female. 11. Willingness and ability to sign an informed consent document. 1. Evidence of CNS involvement. 2. Other active malignancy or history of treatment of any malignancy (excluding nonmelanoma skin cancer) within the previous three years. 3. Previous therapy with Campath. 4. Patients with lowrisk chronic lymphocytic leukemia according to the Rai Staging System. 5. Concurrent immunotherapy. 6. Concurrent use of steroids. 7. Use of an investigational medication or device within 1 month of initiating study therapy. 8. Patients who have had allogeneic bone marrow transplantation. 9. Total serum bilirubin above the upper limit of normal; serum creatinine above the upper limit of normal. 10. AST or ALT &gt; 2.5 times the upper limit of normal. 11. Any condition or any medication which may interfere with the conduct of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>